Released May 7, 2024, before the open
10-Q filed May 7, 2024, 37 days after period end · 0000950170-24-053966
Q1 2024 · 10-Q
Revenue$188.61M$188.61M +7.7% vs Q1 2023−5.9% vs Q4 2023
Net Income-$36.02M-$36.02M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.95-$0.95 N/M vs Q1 2023no prior Q4 2023 on file
Gross Profit$127,242,000+15.3%
Operating Income-$29,337,000N/M
Operating Cash Flow-$18,595,000N/M
Free Cash Flowderived-$29,138,000N/M
Margins · derived
Gross margin67.5%+4.5 pt vs Q1 2023
Operating margin-15.6%+18.5 pt vs Q1 2023
Net margin-19.1%+15.7 pt vs Q1 2023
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $188.61M | $175.20M | $106.42M | $105.59M |
| Net Income | -$36.02M | -$60.94M | -$4.46M | -$5.82M |
| EPS Diluted | -$0.95 | -$1.71 | -$0.22 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR